Status:
UNKNOWN
A Clinical Trial to Explore the Safety and Efficacy of Injections of Macugen When Given Every 6 Weeks in Subjects With AMD
Lead Sponsor:
Eyetech Pharmaceuticals
Collaborating Sponsors:
Pfizer
Conditions:
Age-Related Macular Degeneration (AMD)
Eligibility:
All Genders
50+ years
Phase:
PHASE4
Brief Summary
The purpose of this study is to explore the safety and efficacy of Macugen given as maintenance therapy in patients who have had initial success with another AMD treatment. Patients must have 1, but n...
Eligibility Criteria
Inclusion
- Subfoveal CNV secondary to AMD
- At least 1 but not more than 3 prior treatments for AMD
Exclusion
- Subfoveal scar or subfoveal atrophy
- Significant media opacities, including cataract, which might interfere with visual acuity
Key Trial Info
Start Date :
June 1 2006
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT00354445
Start Date
June 1 2006
Last Update
January 15 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Retina Research Institute of Texas, LLC
Abilene, Texas, United States, 79606